Pfizer slams CMA’s “political” excessive-pricing decision
A lawyer for Pfizer today said the UK antitrust enforcer’s decision to fine the company for excessive pricing of an anti-epilepsy drug was “price regulation, pure and simple”, and attacked the agency’s refusal to examine comparable drugs when assessing Pfizer’s phenytoin prices.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10